Cibc World Markets Corp Has $1.37 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cibc World Markets Corp lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,810 shares of the biopharmaceutical company’s stock after selling 1,561 shares during the quarter. Cibc World Markets Corp’s holdings in Alnylam Pharmaceuticals were worth $1,367,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. raised its holdings in Alnylam Pharmaceuticals by 74.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,062 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 880 shares during the last quarter. Natixis Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 4.5% during the fourth quarter. Natixis Advisors LLC now owns 10,453 shares of the biopharmaceutical company’s stock worth $2,460,000 after buying an additional 451 shares during the last quarter. Poinciana Advisors Group LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $203,000. Commonwealth Equity Services LLC boosted its stake in Alnylam Pharmaceuticals by 23.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 6,537 shares of the biopharmaceutical company’s stock valued at $1,538,000 after acquiring an additional 1,234 shares during the last quarter. Finally, Erste Asset Management GmbH grew its holdings in Alnylam Pharmaceuticals by 60.6% during the 4th quarter. Erste Asset Management GmbH now owns 26,510 shares of the biopharmaceutical company’s stock worth $6,309,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 in the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 11.8 %

NASDAQ:ALNY opened at $283.34 on Friday. The company has a market cap of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The business has a 50 day moving average price of $257.16 and a two-hundred day moving average price of $259.65. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ALNY shares. Bank of America increased their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Royal Bank of Canada increased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $310.22.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.